CytomX Therapeutics Current Ratio 2014-2021 | CTMX

CytomX Therapeutics current ratio from 2014 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
CytomX Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.27B $0.09B 2.90
2021-03-31 $0.40B $0.10B 4.08
2020-12-31 $0.32B $0.10B 3.21
2020-09-30 $0.34B $0.10B 3.34
2020-06-30 $0.37B $0.10B 3.71
2020-03-31 $0.40B $0.11B 3.77
2019-12-31 $0.30B $0.09B 3.54
2019-09-30 $0.34B $0.08B 4.40
2019-06-30 $0.37B $0.08B 4.66
2019-03-31 $0.41B $0.10B 4.21
2018-12-31 $0.45B $0.10B 4.55
2018-09-30 $0.47B $0.09B 5.48
2018-06-30 $0.37B $0.08B 4.41
2018-03-31 $0.37B $0.07B 5.27
2017-12-31 $0.39B $0.06B 6.36
2017-09-30 $0.38B $0.07B 5.28
2017-06-30 $0.34B $0.06B 5.62
2017-03-31 $0.17B $0.04B 4.50
2016-12-31 $0.19B $0.04B 5.26
2016-09-30 $0.18B $0.02B 7.74
2016-06-30 $0.20B $0.02B 8.98
2016-03-31 $0.19B $0.02B 10.85
2015-12-31 $0.19B $0.02B 12.06
2015-09-30 $0.12B $0.01B 8.24
2015-06-30 $0.00B 0.00
2015-03-31 $0.00B 0.00
2014-12-31 $0.00B 0.00
2014-09-30 $0.00B 0.00
2013-12-31 $0.01B $0.00B 2.22
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.352B $0.100B
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86